Dr. Kapil Gururangan graduated from University of California, Berkeley with bachelor degrees in Molecular & Cell Biology and Business Administration, as well as an introduction to research in neuroscience and social psychology. He received his MD from Stanford University School of Medicine, where he performed clinical research under the supervision of Dr. Josef Parvizi focused on non-convulsive seizure detection in critically ill patients using electroencephalography and novel alternative modalities. He has continued to publish in this field as a consultant and scientific advisor for Ceribell, a medical device start-up company co-founded by Dr. Parvizi.

Following an internship in internal medicine, Dr. Gururangan started his neurology residency at Icahn School of Medicine at Mount Sinai. He has been active in research describing neurological consequences of COVID-19 (as part of the Mount Sinai Neuro-COVID-19 Consortium) and scalp electroencephalography correlates of intracranial electrocorticography detections from a responsive neurostimulation system in patients with drug-resistant epilepsy (with Dr. Ji Yeoun Yoo). With the support of an NIH/NINDS R25 grant and the mentorship of Dr. Nathalie Jetté, he is studying seizure outcomes in patients with brain tumor-related epilepsy following neurosurgical intervention.

Following his neurology residency, Dr. Gururangan will be joining University of California, Los Angeles as a fellow in epilepsy and clinical neurophysiology.